ClinicalTrials.gg
RecruitingNCT07131241PH-DyPredUpdated Oct 6, 2026

PH-DyPred: A Multimodal Dynamic Risk Prediction Study in Pulmonary Hypertension

An observational study in Pulmonary Hypertension, sponsored by First Affiliated Hospital of Fujian Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by First Affiliated Hospital of Fujian Medical University · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 85 studies in Hypertension, Pulmonary with a site in China — 31 open to participants now, 36 under way, 5 of them phase 3. Hypertension, Pulmonary · China.

Planned enrollment
16th of 36
1,000 · median 750
Started
2025
with 9 others
Observational
36 of 85
18 open now
Primary completion
2028-06
later than 25 of 35 live
Registered
77th of 85
by date

Among the 85 studies in Hypertension, Pulmonary with a site in China, this one is the 16th largest by planned enrollment of the 36 observational ones that give a count, is one of 10 that started in 2025, is one of 36 observational ones, reaches primary completion later than 25 of the 35 other live ones, and was the 77th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

31 of the 85 studies in Hypertension, Pulmonary with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Hypertension, Pulmonary with a site in China, or all of them as a file.
02

Study summary

Pulmonary hypertension (PH) is a progressive cardiopulmonary disease characterized by elevated pulmonary artery pressure and vascular remodeling, which leads to right heart failure and increased mortality. Despite advances in diagnostics, risk stratification remains limited due to the disease's heterogeneity. This study aims to develop and validate a dynamic risk prediction model for PH by integrating multimodal data-including echocardiography, Cardiac MRI, PET-MR, ECG, biomarkers, and clinical features-using advanced machine learning algorithms. The study will establish a prospective cohort of PH patients to explore predictive markers, stratify prognosis, and provide a scientific basis for early warning and individualized management.

Read the detailed description

This is a prospective, observational cohort study designed to investigate dynamic risk prediction in patients diagnosed with pulmonary hypertension (PH). The study will collect multimodal clinical data-comprising imaging (echocardiography, cardiac MRI, PET-MR), electrocardiographic parameters, blood-based biomarkers, and demographic and clinical information-at baseline and follow-up intervals. The core objective is to develop a data fusion-based prognostic model capable of predicting adverse outcomes such as hospitalization, functional deterioration, or mortality. Machine learning methods will be employed to identify key predictive features. The model will be validated internally and externally across different subgroups. The study seeks to inform individualized risk-based decision-making and advance precision screening in PH care.

In addition, biospecimens will be collected to support comprehensive multi-omics profiling. Whole blood, serum, plasma, urine, and stool samples will be obtained and processed using standardized protocols. Blood-derived samples will be used for genomic, proteomic, metabolomic, and microRNA analyses; urine specimens will support metabolomic and renal biomarker assays; and stool samples will be used for gut microbiome sequencing. All biospecimens will be stored in a secure biobank and linked with clinical, imaging, and longitudinal follow-up data using de-identified subject codes to enable integrated multimodal analyses and facilitate future exploratory investigations of disease mechanisms and biomarker discovery.

Health economic evaluation, including cost-effectiveness and budget impact analyses, will be conducted using collected data on healthcare resource utilization, direct medical costs, and clinical outcomes to inform future policy and reimbursement decision-making.

03

Conditions studied

  • Pulmonary Hypertension

Keywords

  • Pulmonary Hypertension
  • Dynamic Risk Prediction
  • Multimodal Data Fusion
  • Echocardiography
  • Right Heart Function
  • Cardiac Magnetic Resonance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes adult patients (≥18 years) undergoing transthoracic echocardiography. Participants with a pulmonary artery systolic pressure (PASP) ≥35 mmHg on echocardiography will be included as suspected pulmonary hypertension cases. This cohort represents a real-world population at risk for or with early-stage pulmonary hypertension, suitable for developing dynamic risk prediction models based on multimodal data integration.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older
  • Pulmonary artery systolic pressure (PASP) ≥35 mmHg as estimated by echocardiography
  • Provided written

Exclusion criteria

Exclusion Criteria:

  • Severe hepatic or renal insufficiency
  • under active treatment
  • Severe infection
  • Active disease
  • Major surgery within the past 3 months
  • Pregnant or breastfeeding women
  • Severe psychiatric disorder impairing ability to comply with the study protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Suspected PH by Echocardiography

    This study includes a prospective observational cohort of patients with suspected pulmonary hypertension (PH), identified by transthoracic echocardiography (TTE) showing a pulmonary artery systolic pressure (PASP) ≥35 mmHg. No experimental intervention will be applied. Participants will undergo comprehensive data collection, including echocardiography, cardiac magnetic resonance imaging (CMR), electrocardiography (ECG), laboratory testing, and biospecimen sampling (blood, urine, and stool). Follow-up will occur every 6 months for up to 3 years to record clinical outcomes and support the development of a dynamic, multimodal risk prediction model based on artificial intelligence.

06

What researchers measure

Primary outcomes

  1. Time to clinical worsening

    Defined as any of the following: hospitalization for PH, escalation of therapy, 6MWD decrease \>15%, WHO-FC worsening, or death. Measured from baseline.

    Time frame: Up to 36 months

  2. All-cause mortality

    Death from any cause during follow-up, as confirmed by medical records or death registry.

    Time frame: Up to 36 months

Secondary outcomes

  1. Composite risk score performance (AUC)

    Area under the ROC curve for the multimodal model predicting adverse outcomes.

    Time frame: At baseline and follow-up every 6 months

  2. Changes in NT-proBNP levels

    Evaluate biomarker dynamics and predictive value.

    Time frame: Baseline, 6, 12, 24, 36 months

  3. Hospitalization rate for PH-related causes

    Frequency of hospital admissions due to PH complications.

    Time frame: Up to 36 months

  4. Change in Tricuspid Annular Plane Systolic Excursion (TAPSE) Measured by Transthoracic Echocardiography

    TAPSE (mm) will be measured via transthoracic echocardiography to evaluate longitudinal right ventricular systolic function over time.

    Time frame: Baseline, 6, 12, 24, 36 months

  5. Change in Right Ventricular Diameter Measured by Transthoracic Echocardiography

    Right ventricular internal diameter (mm) will be assessed by echocardiography as an indicator of RV structural remodeling.

    Time frame: Baseline, 6, 12, 24, 36 months

  6. Change in Right Ventricular Fractional Area Change (RVFAC) Measured by Transthoracic Echocardiography

    RVFAC (%) will be calculated as the percentage change in RV area between end-diastole and end-systole to assess systolic function.

    Time frame: Baseline, 6, 12, 24, 36 months

  7. Change in Right Ventricular Ejection Fraction (RVEF) Measured by Cardiac Magnetic Resonance Imaging

    RVEF (%) will be quantified using cardiac magnetic resonance imaging to evaluate global systolic function.

    Time frame: Baseline, 6, 12, 24, 36 months

  8. Change in Right Ventricular End-Diastolic Volume Measured by Cardiac Magnetic Resonance Imaging

    Right ventricular end-diastolic volume (mL) will be measured by CMR to assess structural remodeling over time.

    Time frame: Baseline, 6, 12, 24, 36 months

  9. Change in Right Ventricular Mass Measured by Cardiac Magnetic Resonance Imaging

    Right ventricular mass (grams) will be measured by CMR as an index of ventricular hypertrophy and remodeling.

    Time frame: Baseline, 6, 12, 24, 36 months

  10. Change in Right Ventricular FAPI Uptake (SUVmean) Measured by FAPI PET-MR

    tandardized uptake value mean (SUVmean) of FAPI in the right ventricular free wall will be quantified using PET-MR imaging to assess fibroblast activation and myocardial fibrotic activity over time in patients with pulmonary hypertension.

    Time frame: Baseline, 12, 24, and 36 months

  11. Change in Right Ventricular FAPI Uptake (SUVmax) Measured by FAPI PET-MR

    Maximum standardized uptake value (SUVmax) of FAPI in the right ventricle will be measured via PET-MR as an indicator of peak regional fibroblast activation.

    Time frame: Baseline, 12, 24, and 36 months

  12. Change in Right Ventricular FAPI Uptake Ratio Relative to Left Ventricle (SUVratio) Measured by FAPI PET-MR

    The ratio of right ventricular to left ventricular myocardial FAPI uptake (SUVmean RV/SUVmean LV) will be calculated as a normalized index of right ventricular fibrotic remodeling.

    Time frame: Baseline, 12, 24, and 36 months

Other outcomes

  1. Longitudinal changes in health-related quality of life (HRQoL) among patients with suspected or confirmed pulmonary hypertension

    Health-related quality of life (HRQoL) will be assessed using validated instruments such as the EQ-5D-3L and/or the emPHasis-10 questionnaire, both commonly used in pulmonary hypertension research. The emPHasis-10 is a disease-specific, patient-reported outcome measure developed for individuals with pulmonary hypertension, covering domains such as breathlessness, fatigue, social limitation, and psychological burden. Changes in HRQoL scores will be evaluated over time and correlated with clinical events (e.g., hospitalization, WHO functional class deterioration), imaging parameters (e.g., RV function), biomarkers (e.g., NT-proBNP), and model-predicted risk strata. Analyses will include repeated measures ANOVA or mixed-effects modeling to examine within-subject longitudinal chan

    Time frame: Baseline, 6, 12, 24, and 36 months

  2. Area Under the ROC Curve (AUC) of the Multimodal Risk Prediction Model

    The area under the receiver operating characteristic curve (AUC) will be calculated to evaluate the discrimination performance of the multimodal dynamic risk prediction model for adverse outcomes.

    Time frame: Baseline, 12, 24, 36 months

  3. Harrell's Concordance Index (C-index) of the Multimodal Risk Prediction Model

    The concordance index (C-index) will be computed to assess the predictive accuracy of the multimodal risk prediction model.

    Time frame: Baseline, 12, 24, 36 months

  4. Calibration Slope of the Multimodal Risk Prediction Model

    Calibration slope will be estimated to measure agreement between predicted and observed risks in the dynamic risk prediction model.

    Time frame: Baseline, 12, 24, 36 months

  5. Net Benefit Derived from Decision Curve Analysis of the Multimodal Risk Prediction Model

    Net benefit will be calculated using decision curve analysis to evaluate the clinical usefulness of the multimodal risk prediction model in guiding clinical decision-making.

    Time frame: Baseline, 12, 24, 36 months

  6. Correlation between NT-proBNP Concentration (pg/mL) and Right Ventricular Ejection Fraction (RVEF)

    NT-proBNP concentration will be measured in plasma using a standardized immunoassay (pg/mL). Pearson correlation coefficients (r) will be calculated between NT-proBNP levels and right ventricular ejection fraction (RVEF, %) measured by cardiac MRI. Unit of Measure: Correlation coefficient (r)

    Time frame: Baseline, 6, 12, 24, and 36 months

  7. Correlation between NT-proBNP Concentration (pg/mL) and Right Ventricular End-Diastolic Volume (RVEDV)

    NT-proBNP concentration measured by immunoassay (pg/mL) will be correlated with right ventricular end-diastolic volume (mL) assessed by cardiac MRI. Pearson correlation coefficients (r) will be calculated at each follow-up time point. Unit of Measure: Correlation coefficient (r)

    Time frame: Baseline, 6, 12, 24, and 36 months

  8. Correlation between NT-proBNP Concentration (pg/mL) and TAPSE

    NT-proBNP levels (pg/mL) obtained by immunoassay will be correlated with tricuspid annular plane systolic excursion (TAPSE, mm) measured on transthoracic echocardiography using Pearson correlation. Unit of Measure: Correlation coefficient (r)

    Time frame: Baseline, 6, 12, 24, and 36 months

  9. Correlation between NT-proBNP Concentration (pg/mL) and Right Ventricular Longitudinal Strain

    NT-proBNP values (pg/mL) will be correlated with right ventricular longitudinal strain (%) measured by speckle-tracking echocardiography. Pearson correlation coefficients (r) will be reported. Unit of Measure: Correlation coefficient (r)

    Time frame: Baseline, 6, 12, 24, and 36 months

  10. Correlation between NT-proBNP Concentration (pg/mL) and Right Ventricular Fractional Area Change (RVFAC)

    Plasma NT-proBNP level (pg/mL) will be correlated with right ventricular fractional area change (RVFAC, %) measured using echocardiography, and correlation coefficients (r) will be calculated over time. Unit of Measure: Correlation coefficient (r)

    Time frame: Baseline, 6, 12, 24, and 36 months

  11. Association between Baseline NT-proBNP Concentration and Time to Clinical Worsening

    Baseline plasma NT-proBNP levels (pg/mL), measured using a standardized immunoassay, will be analyzed using Cox proportional hazards models to assess their association with time to clinical worsening, defined as hospitalization for pulmonary hypertension, WHO functional class deterioration, or death. Unit of Measure: Hazard ratio (HR)

    Time frame: Up to 36 months

  12. Association between Baseline NT-proBNP Concentration and Model-Predicted Risk Categories

    Baseline NT-proBNP concentration (pg/mL), measured using a standardized immunoassay, will be analyzed using multinomial or logistic regression models to evaluate its association with model-predicted risk categories (e.g., low-, intermediate-, and high-risk strata) generated by the multimodal dynamic risk prediction model. Unit of Measure: Odds ratio (OR)

    Time frame: Baseline, 6, 12, 24, and 36 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Fauvel C, Gomberg-Maitland M, Benza RL. Risk Stratification in Pulmonary Hypertension: We Need to "GoDeeper"! Chest. 2024 Sep;166(3):420-422. doi: 10.1016/j.chest.2024.05.020. No abstract available. PubMed 39260943 ↗
  • Lorenzatti D, Motwani M. Cardiovascular magnetic resonance in pulmonary hypertension: Keeping it simple. Prog Cardiovasc Dis. 2025 May-Jun;90:116-118. doi: 10.1016/j.pcad.2025.04.010. Epub 2025 Apr 26. No abstract available. PubMed 40294712 ↗
  • Kjellstrom B, Lindholm A, Ostenfeld E. Cardiac Magnetic Resonance Imaging in Pulmonary Arterial Hypertension: Ready for Clinical Practice and Guidelines? Curr Heart Fail Rep. 2020 Oct;17(5):181-191. doi: 10.1007/s11897-020-00479-7. PubMed 32870447 ↗
  • Meyer GMB, Spilimbergo FB, Altmayer S, Pacini GS, Zanon M, Watte G, Marchiori E, Hochhegger B. Multiparametric Magnetic Resonance Imaging in the Assessment of Pulmonary Hypertension: Initial Experience of a One-Stop Study. Lung. 2018 Apr;196(2):165-171. doi: 10.1007/s00408-018-0097-7. Epub 2018 Feb 12. PubMed 29435739 ↗
  • van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, Boonstra A, Marques KM, Westerhof N, Vonk-Noordegraaf A. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011 Dec 6;58(24):2511-9. doi: 10.1016/j.jacc.2011.06.068. PubMed 22133851 ↗
  • Small M, Perchenet L, Bennett A, Linder J. The diagnostic journey of pulmonary arterial hypertension patients: results from a multinational real-world survey. Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666231218886. doi: 10.1177/17534666231218886. PubMed 38357903 ↗
  • Hameed A, Condliffe R, Swift AJ, Alabed S, Kiely DG, Charalampopoulos A. Assessment of Right Ventricular Function-a State of the Art. Curr Heart Fail Rep. 2023 Jun;20(3):194-207. doi: 10.1007/s11897-023-00600-6. Epub 2023 Jun 5. PubMed 37271771 ↗
  • Rachedi NS, Tang Y, Tai YY, Zhao J, Chauvet C, Grynblat J, Akoumia KKF, Estephan L, Torrino S, Sbai C, Ait-Mouffok A, Latoche JD, Al Aaraj Y, Brau F, Abelanet S, Clavel S, Zhang Y, Guillermier C, Kumar NVG, Tavakoli S, Mercier O, Risbano MG, Yao ZK, Yang G, Ouerfelli O, Lewis JS, Montani D, Humbert M, Steinhauser ML, Anderson CJ, Oldham WM, Perros F, Bertero T, Chan SY. Dietary intake and glutamine-serine metabolism control pathologic vascular stiffness. Cell Metab. 2024 Jun 4;36(6):1335-1350.e8. doi: 10.1016/j.cmet.2024.04.010. Epub 2024 May 2. PubMed 38701775 ↗
  • Yorke J, Corris P, Gaine S, Gibbs JS, Kiely DG, Harries C, Pollock V, Armstrong I. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J. 2014 Apr;43(4):1106-13. doi: 10.1183/09031936.00127113. Epub 2013 Nov 14. PubMed 24232702 ↗
  • Zhao W, Huang Z, Diao X, Yang Z, Zhao Z, Xia Y, Zhao Q, Sun Z, Xi Q, Huo Y, Xu O, Geng J, Li X, Duan A, Zhang S, Gao L, Wang Y, Li S, Luo Q, Liu Z. Development and validation of multimodal deep learning algorithms for detecting pulmonary hypertension. NPJ Digit Med. 2025 Apr 10;8(1):198. doi: 10.1038/s41746-025-01593-3. PubMed 40205021 ↗
  • Rich S, Haworth SG, Hassoun PM, Yacoub MH. Pulmonary hypertension: the unaddressed global health burden. Lancet Respir Med. 2018 Aug;6(8):577-579. doi: 10.1016/S2213-2600(18)30268-6. Epub 2018 Jun 29. No abstract available. PubMed 30072105 ↗
  • Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Radegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237. No abstract available. PubMed 36017548 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data, including demographic information, clinical characteristics, imaging parameters (echocardiography and CMR), ECG data, laboratory test results, biospecimen profiles (e.g., biomarkers, multi-omics), and follow-up outcomes, will be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: IPD will be made available beginning 24 months after the primary study completion date and remain accessible for up to 24 months.

Access criteria: Qualified researchers with a scientifically sound proposal may request access to the data. Requests will be evaluated by the study steering committee. Approved users must sign a data use agreement ensuring compliance with privacy, ethical, and scientific standards.

Data sharing details ↗ · www.fjmu.edu.cn

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2028, 36 months after the start.

Of 142 non-industry observational studies under Hypertension, Pulmonary, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 167. This study's planned 36 months is below that.

Counting every sponsor, half of 167 studies reached it within 59 months; a quarter within 24 and three quarters within 107.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Aug 20, 2025
StartActual
Jun 27, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2029
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07131241
Lead sponsor
First Affiliated Hospital of Fujian Medical University
Responsible party
Dajun Chai (Professor and Chief Physician, Department of Cardiology, First Affiliated Hospital of Fujian Medical University) — Principal investigator
First posted
Aug 20, 2025
Start date
Jun 27, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Oct 6, 2026

Study contacts

Dajun Chai, MD
Contact
dajunchai-fy@fjmu.edu.cn
0086059187981637
Biyun Chen, MSc
Contact
heraty@sina.com
008613876168899
Dajun Chai, MD
principal investigator · First Affiliated Hospital of Fujian Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion